Want to see ENTA full AI Analyst Report?
Top Page
Enanta Pharmaceuticals
(NASDAQ:ENTA)
Select Model
Select Model
Rating:48Neutral
Price Target:
$15.00
▲(7.07% Upside)
Action:Reiterated
Date:06/24/26
The score is primarily held back by weak financial performance—ongoing losses and negative cash flow despite improving trends and some balance-sheet progress. Technicals are neutral-to-slightly constructive but not strong enough to outweigh fundamentals, while valuation is limited by the negative P/E. Recent corporate updates are mixed, with pipeline advancement offset by an adverse patent litigation decision.
Positive Factors
Late‑stage pipeline progress
Moving zelicapavir into a registrational Phase 2b/3 program represents a durable de‑risking of Enanta's lead antiviral franchise. Late‑stage trials, prior positive Phase 2 signal and Fast Track status position the company to capture structural RSV market opportunity and enable definitive commercialization or high‑value partnering outcomes if results validate efficacy and hospitalization reductions.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow means Enanta remains reliant on external capital or partner funding to advance programs. Even with improved burn, continued outflows create ongoing dilution or financing risk, constrain strategic flexibility, and force prioritization of programs, which can delay or limit investments needed to commercialize late‑stage assets.
Read all positive and negative factors
Positive Factors
Negative Factors
Late‑stage pipeline progress
Moving zelicapavir into a registrational Phase 2b/3 program represents a durable de‑risking of Enanta's lead antiviral franchise. Late‑stage trials, prior positive Phase 2 signal and Fast Track status position the company to capture structural RSV market opportunity and enable definitive commercialization or high‑value partnering outcomes if results validate efficacy and hospitalization reductions.
Read all positive factors
Enanta Pharmaceuticals (ENTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$399.54M
Dividend YieldN/A
Average Volume (3M)132.86K
Price to Earnings (P/E)―
Beta (1Y)1.59
Revenue Growth7.37%
EPS Growth42.85%
CountryUS
Employees120
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.74
Shares Outstanding29,078,380
10 Day Avg. Volume111,827
30 Day Avg. Volume132,863
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.95
Price to Sales (P/S)3.91
P/FCF Ratio-7.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.00Price Target Upside42.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.28
Revenue Forecast (FY)$68.28M
Enanta Pharmaceuticals Business Overview & Revenue Model
Company Description
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily fo...
How the Company Makes Money
Enanta makes money primarily through collaboration and licensing arrangements tied to drug discovery and development. Key revenue streams include (1) royalties on net sales of partnered, commercialized medicines that incorporate Enanta-discovered ...
Enanta Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 06, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Aug 10, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed sentiment with significant advancements in the RSV and immunology programs and a stable financial position. However, it also highlighted challenges with a decline in revenue, increased net loss, and slower enrollment in the RSVPEDs study.Positive Updates
RSV Program Advancements
Progress in developing the first oral antiviral treatment for RSV, with two Phase II studies (RSVPEDs and RSVHR) ongoing and anticipation of reporting data in the second half of 2024.
Negative Updates
Revenue Decline
Total revenue for the quarter decreased to $17.1 million from $17.8 million in the same period in 2023, primarily due to lower royalty rates.
Read all updates
Q2-2024 Updates
Positive
Negative
RSV Program Advancements
Progress in developing the first oral antiviral treatment for RSV, with two Phase II studies (RSVPEDs and RSVHR) ongoing and anticipation of reporting data in the second half of 2024.
Read all positive updates
Company Guidance
During the earnings call for Enanta Pharmaceuticals' fiscal second quarter of 2024, the company provided guidance on several key metrics. For the quarter, total revenue was reported at $17.1 million, primarily from royalty revenue tied to AbbVie's MAVYRET sales. The company updated its expense guidance, projecting research and development expenses to range between $125 million and $145 million, reflecting increased investment in its RSV and new immunology programs. General and administrative expenses are expected to be between $50 million and $60 million, influenced by additional stock compensation and legal costs. Enanta concluded the quarter with approximately $300 million in cash and marketable securities, anticipating this will support its existing operations through the third quarter of fiscal 2027. The company is also advancing its RSV and CSU programs, with milestones including data readouts expected in the second half of 2024 and the introduction of a second immunology program.Enanta Pharmaceuticals Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
38
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 69.21M | 65.32M | 67.64M | 79.20M | 86.16M | 97.07M |
| Gross Profit | 68.00M | 60.74M | 67.64M | 79.20M | 86.16M | 97.07M |
| EBITDA | -46.55M | -70.78M | -104.51M | -123.48M | -119.22M | -104.25M |
| Net Income | -61.98M | -81.89M | -116.05M | -133.82M | -121.75M | -79.00M |
Balance Sheet | ||||||
| Total Assets | 314.70M | 280.73M | 376.65M | 462.27M | 380.59M | 440.86M |
| Cash, Cash Equivalents and Short-Term Investments | 163.77M | 188.86M | 248.19M | 369.91M | 249.23M | 244.00M |
| Total Debt | 186.62M | 201.06M | 226.06M | 26.51M | 26.69M | 6.83M |
| Total Liabilities | 198.12M | 216.01M | 247.84M | 245.54M | 59.26M | 41.43M |
| Stockholders Equity | 116.59M | 64.72M | 128.81M | 216.74M | 321.33M | 399.43M |
Cash Flow | ||||||
| Free Cash Flow | -9.61M | -32.17M | -96.71M | -112.21M | -86.91M | -70.75M |
| Operating Cash Flow | -7.84M | -19.27M | -78.76M | -103.15M | -84.78M | -70.00M |
| Investing Cash Flow | -59.54M | 40.35M | 58.23M | -53.58M | 54.90M | 36.99M |
| Financing Cash Flow | 42.10M | -26.62M | -27.63M | 198.13M | 20.03M | 3.08M |
Enanta Pharmaceuticals Technical Analysis
Negative
14.01
Price Trends
13.35
Negative
13.49
Negative
13.23
Negative
Market Momentum
0.06
Positive
45.91
Neutral
26.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENTA, the sentiment is Negative. The current price of 14.01 is above the 20-day moving average (MA) of 13.94, above the 50-day MA of 13.35, and above the 200-day MA of 13.23, indicating a bearish trend. The MACD of 0.06 indicates Positive momentum. The RSI at 45.91 is Neutral, neither overbought nor oversold. The STOCH value of 26.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENTA.
Enanta Pharmaceuticals Risk Analysis
Enanta Pharmaceuticals disclosed 50 risk factors in its most recent earnings report. Enanta Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enanta Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $398.97M | 5.04 | 41.40% | ― | ― | ― | |
56 Neutral | $615.14M | -7.19 | -32.33% | ― | ― | 38.99% | |
56 Neutral | $1.27B | -6.74 | -51.34% | 14.68% | ― | 94.97% | |
52 Neutral | $617.83M | -2.30 | -56.45% | ― | ― | 37.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $399.54M | -4.80 | -64.04% | ― | 7.37% | 42.85% | |
42 Neutral | $298.31M | -1.23 | -181.70% | ― | ― | 17.61% |
* Healthcare Sector Average
ENTA
Enanta Pharmaceuticals
13.16
5.43
70.25%
ABEO
Abeona Therapeutics
6.48
-0.27
-4.00%
TECX
Tectonic Therapeutic
32.07
10.15
46.30%
ALLO
Allogene Therapeutics
1.77
0.45
34.09%
JBIO
Jade Biosciences
19.67
10.98
126.35%
NMRA
Neumora Therapeutics, Inc.
1.63
-0.33
-16.84%
Enanta Pharmaceuticals Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Enanta Pharmaceuticals Establishes Flexible At-The-Market Offering
Neutral
Jul 2, 2026
On July 2, 2026, Enanta Pharmaceuticals entered into an Open Market Sale Agreement with Jefferies LLC that allows the company to sell up to $75 million of its common stock from time to time in an at-the-market offering under an existing shelf regi...
Business Operations and StrategyLegal Proceedings
Enanta Faces Patent Setback in Paxlovid Litigation
Negative
Jun 23, 2026
Enanta Pharmaceuticals, Inc. reported that on June 23, 2026, the U.S. Court of Appeals for the Federal Circuit upheld a December 2024 summary judgment from the District of Massachusetts, ruling that the claims of its U.S. Patent No. 11,358,953 are...
Business Operations and StrategyProduct-Related Announcements
Enanta Advances RSV Antiviral Zelicapavir to Registrational Trial
Positive
Jun 18, 2026
On June 18, 2026, Enanta announced it will advance its RSV antiviral candidate zelicapavir into a registrational Phase 2b/3 trial in high-risk adult outpatients, following a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administrat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.